Convergent targeting of FUNDC1‐dependent mitophagy sensitises and overcomes resistance to EGFR inhibition
Clinical and Translational Medicine · 2026-05 · 16 (5)
DOI: 10.1002/ctm2.70685 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 18.05.2026. Verfasst von Fan Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Mitophagy, Drug Resistance, Neoplasm, Membrane Proteins, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of China, Natural Science Foundation of Zhejiang Province, Taishan Scholar Foundation of Shandong Province.
Abstract (Originalsprache)
Combination therapies are critical for enhancing and prolonging the efficacy of EGFR inhibitors. Here, we uncover FUNDC1‐dependent mitophagy as a key protective mechanism in EGFR‐mutant non‐small cell lung cancer (NSCLC). We discover that nitidine, a bioactive component of the traditional Xihuang Pill formulation, synergises with the EGFR inhibitor osimertinib. Mechanistically, nitidine and osimertinib synergistically disrupt FUNDC1‐mediated mitophagy, leading to mitochondrial dysfunction and accumulation of reactive oxygen species in EGFR‐mutant NSCLC. We further show that both osimertinib and nitidine decrease HIF‐1α protein levels, thereby downregulating FUNDC1 expression. Nitidine‐induced downregulation of HIF‐1α and FUNDC1 depends on the mitochondrial transporter ABCB6. Notably, acquired resistance to osimertinib exhibits adaptive downregulation of FUNDC1, rendering resistant EGFR‐mutant NSCLC cells more sensitive to nitidine. Collectively, these findings position nitidine as a promising therapeutic strategy to enhance the efficacy of EGFR inhibitors and overcome osimertinib resistance in EGFR‐mutant NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
- Institute of Clinical Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- National Clinical Research Center for Chinese Medicine, Tianjin, China.
- Department of Central Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Engineering Laboratory of Urinary Organ and Functional Reconstruction of Shandong Province, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Förderung
- Ministry of Science and Technology of China
- Natural Science Foundation of Zhejiang Province
- Taishan Scholar Foundation of Shandong Province
- National Natural Science Foundation of China
- Shandong Provincial Natural Science Foundation
Zitieren
APA
Xu, F., Wang, X., Li, M., Li, Y., Li, X., Yan, Q., Kong, F., Huang, Q., Cao, X., & Xue, Y. (2026). Convergent targeting of FUNDC1‐dependent mitophagy sensitises and overcomes resistance to EGFR inhibition. Clinical and Translational Medicine, 16(5). https://doi.org/10.1002/ctm2.70685
Vancouver
Xu F, Wang X, Li M, Li Y, Li X, Yan Q, et al. Convergent targeting of FUNDC1‐dependent mitophagy sensitises and overcomes resistance to EGFR inhibition. Clinical and Translational Medicine. 2026;16(5). doi:10.1002/ctm2.70685
BibTeX
@article{Xu2026,
author = {Xu, Fan and Wang, Xiaoshan and Li, Min and Li, Yi and Li, Xiaojuan and Yan, Qingqing and Kong, Fanming and Huang, Qihong and Cao, Xin and Xue, Ying},
title = {Convergent targeting of FUNDC1‐dependent mitophagy sensitises and overcomes resistance to EGFR inhibition},
journal = {Clinical and Translational Medicine},
year = {2026},
volume = {16},
number = {5},
doi = {10.1002/ctm2.70685}
}
EUVIMED